Showing session: reset
Novel Immune and Targeted Therapies for Hematologic Malignancies and Solid Tumors
- Sort by:
- Browse by:
- Free
- Unknown permission
for presentation
Chairperson
Joseph Paul Eder
Yale University, New Haven, CT, United States
- Free
- slides video
- audio + slides
- All slides included
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Renier Brentjens
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Free
- Coming soon
- Some slides withheld
Discussant
Carl H. June
Abramson Cancer Ctr. of Univ. of Penn., Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
Eytan Stein
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
John C. Byrd
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
- Free
- slides video
- audio + slides
- All slides included
Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome
Adil I. Daud
UCSF School of Medicine, San Francisco, CA, United States
- Free
- slides video
- audio + slides
- All slides included
MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States